Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function
<p>Abstract</p> <p>Type 1A diabetes mellitus (T1ADM) is a progressive autoimmune disease mediated by T lymphocytes with destruction of beta cells. Up to now, we do not have precise methods to assess the beta cell mass, "<it>in vivo</it>" or "<it>ex-...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-12-01
|
Series: | Diabetology & Metabolic Syndrome |
Online Access: | http://www.dmsjournal.com/content/1/1/25 |
id |
doaj-00df1b8fd126464f88443d0598cb53ed |
---|---|
record_format |
Article |
spelling |
doaj-00df1b8fd126464f88443d0598cb53ed2020-11-24T21:55:48ZengBMCDiabetology & Metabolic Syndrome1758-59962009-12-01112510.1186/1758-5996-1-25Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell functionDib Sergio AGomes Marilia B<p>Abstract</p> <p>Type 1A diabetes mellitus (T1ADM) is a progressive autoimmune disease mediated by T lymphocytes with destruction of beta cells. Up to now, we do not have precise methods to assess the beta cell mass, "<it>in vivo</it>" or "<it>ex-vivo</it>". The studies about its genetic susceptibility show strong association with class II antigens of the HLA system (particularly DQ). Others genetics associations are weaker and depend on the population studied. A combination of precipitating events may occur at the beginning of the disease. There is a silent loss of immune-mediated beta cells mass which velocity has an inverse relation with the age, but it is influenced by genetic and metabolic factors. We can predict the development of the disease primarily through the determination of four biochemically islet auto antibodies against antigens like insulin, GAD65, IA2 and Znt8. Beta cell destruction is chronically progressive but at clinical diagnosis of the disease a reserve of these cells still functioning. The goal of secondary disease prevention is halt the autoimmune attack on beta cells by redirecting or dampening the immune system. It is remains one of the foremost therapeutic goals in the T1ADM. Glycemic intensive control and immunotherapeutic agents may preserve beta-cell function in newly diagnosed patients with T1ADM. It may be assessed through C-peptide values, which are important for glycemic stability and for the prevention of chronic complications of this disease. This article will summarize the etiopathogenesis mechanisms of this disease and the factors can influence on residual C-peptide and the strategies to it preservation.</p> http://www.dmsjournal.com/content/1/1/25 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dib Sergio A Gomes Marilia B |
spellingShingle |
Dib Sergio A Gomes Marilia B Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function Diabetology & Metabolic Syndrome |
author_facet |
Dib Sergio A Gomes Marilia B |
author_sort |
Dib Sergio A |
title |
Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function |
title_short |
Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function |
title_full |
Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function |
title_fullStr |
Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function |
title_full_unstemmed |
Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function |
title_sort |
etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function |
publisher |
BMC |
series |
Diabetology & Metabolic Syndrome |
issn |
1758-5996 |
publishDate |
2009-12-01 |
description |
<p>Abstract</p> <p>Type 1A diabetes mellitus (T1ADM) is a progressive autoimmune disease mediated by T lymphocytes with destruction of beta cells. Up to now, we do not have precise methods to assess the beta cell mass, "<it>in vivo</it>" or "<it>ex-vivo</it>". The studies about its genetic susceptibility show strong association with class II antigens of the HLA system (particularly DQ). Others genetics associations are weaker and depend on the population studied. A combination of precipitating events may occur at the beginning of the disease. There is a silent loss of immune-mediated beta cells mass which velocity has an inverse relation with the age, but it is influenced by genetic and metabolic factors. We can predict the development of the disease primarily through the determination of four biochemically islet auto antibodies against antigens like insulin, GAD65, IA2 and Znt8. Beta cell destruction is chronically progressive but at clinical diagnosis of the disease a reserve of these cells still functioning. The goal of secondary disease prevention is halt the autoimmune attack on beta cells by redirecting or dampening the immune system. It is remains one of the foremost therapeutic goals in the T1ADM. Glycemic intensive control and immunotherapeutic agents may preserve beta-cell function in newly diagnosed patients with T1ADM. It may be assessed through C-peptide values, which are important for glycemic stability and for the prevention of chronic complications of this disease. This article will summarize the etiopathogenesis mechanisms of this disease and the factors can influence on residual C-peptide and the strategies to it preservation.</p> |
url |
http://www.dmsjournal.com/content/1/1/25 |
work_keys_str_mv |
AT dibsergioa etiopathogenesisoftype1diabetesmellitusprognosticfactorsfortheevolutionofresidualbcellfunction AT gomesmariliab etiopathogenesisoftype1diabetesmellitusprognosticfactorsfortheevolutionofresidualbcellfunction |
_version_ |
1725861243082768384 |